RDHL - RedHill Biopharma Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.35
+0.18 (+2.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.17
Open6.82
Bid6.20 x 800
Ask7.83 x 800
Day's Range6.20 - 7.15
52 Week Range5.13 - 9.57
Volume339,868
Avg. Volume65,315
Market Cap190.201M
Beta (3Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-1.47
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.67
Trade prices are not sourced from all markets
  • GlobeNewswire

    RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V. (SIX:COPN) (“Cosmo”). The strategic collaboration includes an exclusive license agreement for the U.S. rights to Aemcolo® (rifamycin) and a simultaneous private investment by Cosmo of $36.3 million in RedHill at $7.00 per American Depositary Share (ADS), representing approximately 13.5% over the closing price on October 17, 2019, with a 180-day transfer restriction.

  • GlobeNewswire

    RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced its support of a number of prevention and awareness initiatives for Stomach Cancer Awareness Month, including its sponsorship of the No Stomach For Cancer’s (NSFC) Spotlight on Stomach Cancer Symposium. The symposium will take place on Saturday, October 26, 2019, from 8 a.m. - 2 p.m. MST at the University of Arizona in Tucson, Arizona.

  • GlobeNewswire

    RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced  full Week 52 results for all subjects in the previously announced positive Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (the “MAP US study”) and supportive top-line results from the open-label extension Phase 3 study (the “MAP US2 study”). The full Week 52 results of blinded treatment in the MAP US Phase 3 study with RHB-104 were consistent with the previously reported positive outcomes of the study.

  • GlobeNewswire

    RedHill Biopharma Provides H2/2019 R&D Update

    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 26, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire

    RedHill Biopharma to Present at Upcoming Investor Conferences in September

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 27, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire

    RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will present data from the positive Phase 3 clinical studies of RHB-105 (Talicia®)1 for H. pylori infection and RHB-104 for Crohn’s disease at the upcoming American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting (October 25-30, 2019). In addition, an oral presentation on RHB-105 (Talicia) was also accepted for presentation at the XXXIInd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer of the European Helicobacter and Microbiota Study Group (EHMSG 2019) (September 5-7, 2019).

  • GlobeNewswire

    RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights

    Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA.

  • ACCESSWIRE

    RedHill Biopharma Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 23, 2019 / RedHill Biopharma Ltd. (NASDAQ: RDHL ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 8:30 AM ...

  • 3 Small-Caps That Look Like Bargains at Current Trading Levels
    TheStreet.com

    3 Small-Caps That Look Like Bargains at Current Trading Levels

    No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .

  • GlobeNewswire

    RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019

    TEL-AVIV, Israel and RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will report its second quarter 2019 financial results and operational highlights on Tuesday, July 23, 2019. The Company will host a conference call on Tuesday, July 23, 2019 at 8:30 a.m. EDT to review the second quarter 2019 financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events.

  • 3 Biotech Stocks That Could Double Your Money
    Motley Fool

    3 Biotech Stocks That Could Double Your Money

    Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.

  • GlobeNewswire

    RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®

    TEL-AVIV, Israel and RALEIGH, N.C., July 03, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Talicia® (RHB-105)1 for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.

  • GlobeNewswire

    RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections

    TEL-AVIV, Israel and RALEIGH, N.C., June 10, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent covering RHB-104 for Crohn’s disease and RHB-204 for Mycobacterium avium complex (MAC) disease, the most common cause of pulmonary nontuberculous mycobacteria (NTM) infections1. Once granted, the patent is expected to be valid until at least 2029.

  • GlobeNewswire

    RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer

    TEL-AVIV, Israel and RALEIGH, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. June S. Almenoff, M.D., Ph.D., FACP, as Chief Scientific Officer. Dr. Almenoff, an accomplished pharma executive with extensive gastroenterology and infectious diseases expertise, will lead the Company’s commercial strategy as it relates to medical and scientific matters, including the medical affairs activities for Talicia® (RHB-105)1 in preparation for potential U.S. commercial launch in the fourth quarter of 2019.

  • GlobeNewswire

    RedHill Biopharma to Present at 2019 BIO International Convention

    TEL-AVIV, Israel and RALEIGH, N.C., May 23, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, Senior Vice President of Business Development and Licensing, will present a corporate overview at the 2019 BIO International Convention on Monday, June 3, 2019, at 1:30 p.m. EDT at the Pennsylvania Convention Center, Philadelphia, PA. A copy of the presentation to be delivered by Mr. Frish will be available on the Company's website and may be viewed at: http://ir.redhillbio.com. RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.

  • GlobeNewswire

    RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch

    TEL-AVIV, Israel and RALEIGH, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that it is expanding its commercial management team with several key executive hires ahead of the potential U.S. launch of Talicia®. The Company has appointed Rob Jackson as Vice President of Marketing, Robert J. Gilkin, Jr. as Vice President of Market Access and Steven Thomasian as Vice President of Supply Chain.

  • GlobeNewswire

    RedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights

    Key Highlights and Upcoming Milestones: NDA submitted to the FDA for Talicia® for H. pylori infection, with potential U.S. commercial launch in Q4/2019, assuming FDA.

  • GlobeNewswire

    RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection

    TEL-AVIV, Israel and RALEIGH, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that, following a positive pre-NDA meeting held recently with the U.S. Food and Drug Administration (FDA), it has submitted a New Drug Application (NDA) to the FDA for Talicia® (RHB-105)1 for the treatment of H. pylori infection. The NDA was submitted under the 505(b)(2) regulatory pathway.

  • GlobeNewswire

    RedHill Biopharma to Host First Quarter 2019 Financial Results Conference Call on May 7, 2019

    TEL-AVIV, Israel and RALEIGH, N.C., April 30, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it will report its first quarter 2019 financial results and operational highlights on Tuesday, May 7, 2019. The Company will host a conference call on Tuesday, May 7, 2019 at 8:30 a.m. EDT to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events.

  • GlobeNewswire

    RedHill Biopharma to Present at Three Conferences in April

    TEL-AVIV, Israel and RALEIGH, N.C., April 04, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire

    RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference

    TEL-AVIV, Israel and RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, senior vice president of business development and licensing, will present a corporate overview at the BIO-Europe Spring 2019 conference on Wednesday, March 27, 2019, at 9:45 a.m. CET at the Messe Wien Exhibition and Congress Center in Vienna, Austria. A copy of the presentation to be delivered by Mr. Frish will be available on the Company's website and may be viewed at: http://ir.redhillbio.com.

  • GlobeNewswire

    RedHill Biopharma to Present at the 31st Annual ROTH Conference

    TEL-AVIV, Israel and RALEIGH, N.C., March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, senior vice president of business development and licensing, will present a corporate overview at the 31st Annual ROTH Conference on Tuesday, March 19, 2019, at 1:00 p.m. PDT at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. The presentation will be broadcast live and available via replay for 30 days on the Company's website, http://ir.redhillbio.com/events.